Garri Zmudze Speaks with The Horizons Life Ahead of the Longevity Investors Conference
LongeVC co-founder Garri Zmudze was interviewed by THE HORIZONS Life ahead of the Longevity Investors Conference in Gstaad. Garri discussed the sector's growth, projected to reach $67B by 2035, and how LongeVC separates real science from investment narratives: peer-reviewed validation, clear clinical endpoints, and mechanisms that hold up to scrutiny.
He also shared the personal story behind co-founding the firm and highlighted the work of portfolio companies Rubedo Life Sciences and Unnatural Products, as well as LongeVC partner Insilico Medicine.